Quinn Opportunity Partners LLC Takes Position in Replimune Group, Inc. $REPL

Quinn Opportunity Partners LLC bought a new position in shares of Replimune Group, Inc. (NASDAQ:REPL) in the third quarter, HoldingsChannel reports. The firm bought 650,721 shares of the company’s stock, valued at approximately $2,727,000.

Several other large investors also recently modified their holdings of REPL. BNP Paribas Financial Markets raised its position in Replimune Group by 37.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after purchasing an additional 1,879 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Replimune Group in the 2nd quarter worth approximately $69,000. Russell Investments Group Ltd. grew its position in shares of Replimune Group by 3,638.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after buying an additional 7,569 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Replimune Group by 2,020.8% during the second quarter. Tower Research Capital LLC TRC now owns 9,692 shares of the company’s stock valued at $90,000 after buying an additional 9,235 shares during the period. Finally, Letko Brosseau & Associates Inc. purchased a new position in shares of Replimune Group during the second quarter valued at approximately $100,000. 92.53% of the stock is owned by institutional investors.

Replimune Group Stock Performance

Replimune Group stock opened at $7.14 on Friday. Replimune Group, Inc. has a fifty-two week low of $2.68 and a fifty-two week high of $13.24. The stock’s 50 day simple moving average is $7.73 and its two-hundred day simple moving average is $7.65. The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.60 and a current ratio of 5.60. The stock has a market cap of $589.55 million, a price-to-earnings ratio of -2.08 and a beta of 0.72.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Tuesday, February 3rd. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.08. As a group, analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on REPL. Piper Sandler raised their price target on Replimune Group from $13.00 to $14.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Replimune Group in a research report on Monday, December 29th. Finally, Wedbush upped their price objective on shares of Replimune Group from $18.00 to $19.00 and gave the stock an “outperform” rating in a report on Wednesday, February 4th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $10.00.

Replimune Group Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.